	TO RESEARCH NEULAND INDIA PRIV ANCE SHEET AS ON MARCH 31, 2015	ATE LIMITED		· •	Call Research Heutand Init
	······································				Amount in 🤻
			AS ON		AS ON
•	PARTICULARS	NOTES	MARCH 31,		MARCH 31, 2014
Ì	EQUITY AND LIABILITIES:				
1	SHAREHOLDERS' FUNDS				
	(a) Share Capital	3	51,10,163		51,10,163
	(b) Reserves and Surplus	4	(47,90,228)		(42,96,916
				3,19,935	8,13,247
2	CURRENT LIABILITIES				
	(a) Trade Payables	5	28,090		56,180
	(b) Other Current Liabilities	6	13,85,573		8,44,808
				14,13,663	9,00,988
	TOTAL			17,33,598	17,14,235
		•			
ļI	ASSETS:				
1	CURRENT ASSETS				
	(a) Cash and Bank Balances	7	17,33,598		17,02,033
	(b) Short-term Loans and Advances	8	-		12,202
				17,33,598	17,14,235
•	TOTAL			17,33,598	17,14,235
	SIGNIFICANT ACCOUNTING POLICIES	- 2			
	accompanying notes form an integral part of our report attached	the Financial Statem		on behalf of the Bo	pard
or I	3. Srinivasa Rao & Co.		\cap		··· 21
	tered Accountants			/ A	· A
ICAI	Firm Regn No.008763S	T			2M
сн А	NAND		D. Sucheth Rao	/ ~	Saharsh Rao
Part		•	Director		irector
	nbership No: 222732				/
	e: Hyderabad :: May 7, 2015		Henjek Rotmensch '	Bring]

•

÷

4,

CATO RESEARCH NEULAND INDIA PRIV		121 2015		CRNI Cato Research Replaced Judia
STATEMENT OF PROPILARD LOSS FOR THE		151,2015		Amount in ₹
PARTICULARS	NOTES	FOR THE YEAR ENDED MARCH 31, 2015		FOR THE YEAR ENDED MARCH 31, 2014
INCOME:				
1 Revenue from Operations (Net)	9		-	-
2 Other Income	10	2	5,008	2,14,302
TOTAL		2	5,008	2,14,302
EXPENDITURE:			11	
3 Employee Benefits Expense	. 11	4,7	9,265	19,56,665
4 Other Expenses	12		9,055	41,503
TOTAL		5,1	8,320	19,98,168
PROFIT / (LOSS) BEFORE TAX		(4,9	3,312)	(17,83,866)
5 Tax Expense (a) Current Tax			-	-
PROFIT / (LOSS) AFTER TAX		. (4,9	3,312)	(17,83,866)
6 EARNINGS PER SHARE Basic Earnings Per Share (in ₹) Diluted Earnings Per Share (in ₹) Face Value Per Share (in ₹)	15		(0.97) (0.97) 10	(3.49) (3.49) 10
SIGNIFICANT ACCOUNTING POLICIES	2			
The accompanying notes form an integral part of	f the Financial Stateme	ents.		and a second
Per our report attached		For and on behalf	of the Bo	ard
For B, Srinivasa Rao & Co.		\wedge	Λ	· · ·
Chartered Accountants ICAI Firm Regn No.008763S	1	- Mlk		Wh
CH ANAND Partner		D. Sucheth Rao Director	10	D. Saharsh Rao /
Membership No: 222732		G. H. Brow)	
Place: Hyderabad Date: May 7, 2015		Henjek Rotmensch Director	/	

.

•

й. г

,

CASH FLOW STATEMENT FOR THE YEAR ENDED MARCH 31, 2015	and the second	Amount in ₹
PARTICULARS	FOR THE YEAR ENDED MARCH 31, 2015	FOR THE YEAR ENDED MARCH 31, 2014
CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit Before Tax	(4,93,312)	(17,83,866)
Adjustments Less: Interest Income Operating Profit Before Working Capital Changes	(25,008) . (5,18,320)	- - (17,83,866)
Add / Less : Working Capital Changes Loans & Advances Trade Payables and Other Liabilities Cash flow from Operating Activities Add: Income Tax Refund Net Cash from Operating Activities (A)	5,12,675 (5,645) 37,210 31,565	48,53,363 (43,21,264) (12,51,767) <u>33,530</u> (12,18,237)
CASH FLOW FROM INVESTING ACTIVITIES (B)	-	-
CASH FLOW FROM FINANCING ACTIVITIES (C)	-	
Net Increase/(decrease) in Cash & Cash Equivalents (A+B+C)	31,565	(12,18,237)
Opening Balance of Cash & Cash Equivalents Closing Balance of Cash & Cash Equivalents (Refer Note 7 for details of cash and cash equivalents)	17,02,033 17,33,598	29,20,270 17,02,033

Per our report attached For B. Srinivasa Rao & Co. Chartered Accountants ICAI Firm Regn No.008763S

~ ~

CH ANAND Partner Membership No: 222732

Place: Hyderabad Date: May 7, 2015 For and on behalf of the Board

D. Suci Directo cheth Rao

D. Saharsh Rao Director

Henjek Rotmensch Director

1. CORPORATE INFORMATION

Cato Research Neuland India Private Limited ("the Company") is a private company domiciled in India and incorporated under the provisions of the Companies Act, 1956. The Company is formed as a joint venture between Neuland Laboratories Limited (70%) and Cato Research Israel Limited (30%). Neuland Laboratories Limited is based in Hyderabad, India whereas Cato Research Israel Limited is situated in Israel. The main object of the Company is to provide contract research organization services to customer in the following areas.

- (i) Consulting services relating to drug discovery and development services;
- (ii) Design, conduct and manage phase I through phase IV clinical studies;
- (iii) Data processing and data management activities; and
- (iv) Regulatory affairs relating to the intellectual property rights.

2. SIGNIFICANT ACCOUNTING POLICIES:

- A. Basis of Accounting and use of estimates
 - (i) Financial statements are prepared under the historical cost convention, on accrual basis of accounting in accordance with the accounting principles generally accepted in India and in compliance with the provisions of Companies Act 1956, and comply with the mandatory accounting standards specified in Companies (Accounting Standard) Rules 2006 (which continue to be applicable in respect Section 133 of the Companies Act, 2013 in terms of General Circular 15/2013 dated September 13, 2013 of the Ministry of Corporate Affairs).
 - (ii) The preparation of financial statements, in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the results of operations during the reporting period end. Although these estimates are based upon management's best knowledge of current events and actions, actual results could differ from these estimates.
- B. Revenue Recognition

Service revenue is recognised on the basis of set milestones by the Company. The Company recognises service revenue when the following conditions are fulfilled:

- (i) Definite understanding / arrangement for providing service(s) exist.
- (ii) Agreed service(s) has been delivered to the client.
- (iii) The client acknowledges the receipt of service(s) and the flow of income is fixed or established.
- C. Foreign currency Transactions

Transactions in foreign exchange are accounted for at the average exchange rate for the month of transaction. Foreign currency monetary items are reported using exchange rates prevailing at the close of the year and exchange difference arising there from is charged/credited to the Statement of Profit & Loss. Non-monetary items which are carried in terms of historical cost denominated in a foreign currency are reported using the exchange rate at the date of the transaction.

D. Earnings per Share

Basic earnings per share are calculated by dividing the net profit or loss for the year attributable to equity shareholders by the weighted average number of equity shares outstanding during the year. For the purpose of calculating diluted earnings per share, the net profit or loss for the year

attributable to equity shareholders and the weighted average number of shares outstanding during the year are adjusted for the effects of all dilutive potential equity shares.

E. Taxation

Provision for current tax is made after taking into consideration benefits admissible under the provisions of Income Tax Act, 1961.Deferred tax resulting from "timing differences" between book and taxable profit is accounted for using the tax rates and laws that have been enacted or substantively enacted as on the balance sheet date. The deferred tax assets pertaining to carried forward losses and unabsorbed depreciation are recognized only to the extent that there is a virtual certainty that these assets are realized. The deferred tax assets pertaining to other items are recognized to the extent that there is a reasonable certainty that the same can be realized.

F. Contingencies and Provisions

A provision is recognized when the Company has a present obligation as a result of past events. Provisions are not discounted to present value and are determined based on the best estimate of the expenditure required to settle the obligation at the balance sheet date. These are reviewed at each balance sheet date and adjusted to reflect the current best estimate.

Contingent liabilities are disclosed after careful examination of the facts and legal aspects of the matter involved.

Cato Research Healand India

3. SHARE CAPITAL

			Amount in ₹
	PARTICULARS	AS ON MARCH 31, 2015	AS ON MARCH 31, 2014
1	AUTHORISED		
_	30,00,000 Equity Shares of ₹10 each	3,00,00,000	3,00,00,000
2	ISSUED		
	12,95,990 Equity Shares of₹10 each, fully paid	1,29,59,900	1,29,59,900
	(March 31, 2014 – 12,95,990 Equity Shares of ₹10 each)		
3	SUBSCRIBED CAPITAL		
	12,95,990 Equity Shares of₹10 each, fully paid	1,29,59,900	1,29,59,900
	(March 31, 2014 – 12,95,990 Equity Shares of ₹10 each)		
4	PAID UP CAPITAL		
	4,23,797Equity Shares of ₹10 each fully paid up (<i>March 31, 2014 – 4,23,797 Equity Shares of ₹10 each</i>)	42,37,970	42,37,970
	8,72,193 Equity Shares of ₹10 each, ₹1 paid up	8,72,193	8,72,193
	(March 31, 2014 – 8,72,193 Equity Shares of ₹10 each, ₹1 paid up)		
		51,10,163	51,10,163

a. Reconciliation of number of equity shares outstanding at the beginning and at the end of the year

PARTICULARS	AS ON MARCH 31, 2015	AS ON MARCH 31, 2014
Number of equity shares outstanding at the beginning of the year	12,95,990	12,95,990
Add / Less: Adjustments during the year		
Number of equity shares outstanding at the end of the year	12,95,990	12,95,990

b. Terms / Rights attached to equity shares

The Company has only one class of equity shares having par value of ₹ 10 per share. Each shareholder of equity shares is entitled to one vote per share. The Company declares and pays dividend in Indian Rupees. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting.

In the event of liquidation of the Company, the holders of the equity shares will be entitled to receive remaining assets of the Company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholder.

c. Details of Shareholders holding more than 5% shares in the Company

	NAME OF THE		ON 31, 2015	AS ON MARCH 31, 2014	
SHARE HOLDER	NO. OF SHARES	% OF HOLDING	NO. OF SHARES	% OF HOLDING	
Eq	uity Shares of ₹10 each				
1	Neuland Laboratories Limited (35,000 equity shares fully paid up and 8,72,193 equity shares ₹1 paid up)	9,07,193	70.00	9,07,193	70.00
2	Cato Research Israel Limited	3,88,797	30.00	3,88,797	30.00

d. Shareholding by Holding Company

NAME OF THE	AS ON MARCH 31, 2015		AS ON MARCH 31, 2014	
SHARE HOLDER	NO. OF SHARES	% OF HOLDING	NO. OF SHARES	% OF HOLDING
Equity Shares of ₹10 each Neuland Laboratories Limited (35,000 equity shares fully paid up and 8,72,193 equity shares ₹1 paid up)	9,07,193	70.00	9,07,193	70.00

4. RESERVES AND SURPLUS

			Amount in ₹	
		AS ON	AS ON	
	PARTICULARS	MARCH 31, 2015	MARCH 31, 2014	
1	Deficit			
	Balance as per last Financial Statements	(42,96,916)	(25,13,050)	
	Profit / (Loss) for the year	(4,93,312)	(17,83,866)	
	Net Deficit	(47,90,228)	(42,96,916)	
	TOTAL	(47,90,228)	(42,96,916)	

5. TRADE PAYABLES

		Amount in ₹	
PARTICULARS	AS ON	AS ON	
	MARCH 31, 2015	MARCH 31, 2014	
1 Trade Payables	28,090	56,180	
	28,090	56,180	

Cato Research Neuland India

6. OTHER CURRENT LIABILITIES

			Amount in ₹	
		AS ON	AS ON	
	PARTICULARS	MARCH 31, 2015	MARCH 31, 2014	
1	Payable to Related Party - Holding Company	13,85,573	8,44,808	
		13,85,573	8,44,808	

7. CASH AND BANK BALANCES

<u></u>		NON-CI	URRENT	CUR	Amount in ₹ RENT
	PARTICULARS	AS ON MARCH 31, 2015	AS ON MARCH 31, 2014	AS ON MARCH 31, 2015	AS ON MARCH 31, 2014
1	CASH AND CASH EQUIVALENTS Balances with Scheduled Banks				
	- On Current Accounts	-	-	16,97,421	16,60,211
2	Cash on Hand	-	-	36,177	41,822
	-			17,33,598	17,02,033

8. LOANS AND ADVANCES

	NON-CI	IDDENIT	CUR	Amount in ₹ RENT
PARTICULARS	AS ON MARCH 31, 2015	AS ON MARCH 31, 2014	AS ON MARCH 31, 2015	AS ON MARCH 31, 2014
Advance Payment against Taxes - Income Tax		-	-	12,202
			· · · · · · · · · · · · · · · · · · ·	12,202
The above amounts includes Secured, Considered Good	-	-	-	
Secured, Considered Doubtful Unsecured, Considered Good Unsecured, Considered	-	-	-	12,20.
Doubtful	-	- -	-	12,20

Cato Research Hanland India

9. REVENUE FROM OPERATIONS

	x	Amount in ₹
	FOR THE YEAR	FOR THE YEAR
PARTICULARS	ENDED	ENDED
	MARCH 31, 2015	MARCH 31, 2014
Revenue		
Service Fees		_
Revenue from Operations (Gross)	-	-
Less: Taxes		_
Revenue from Operations (Net)		. +

10. OTHER INCOME

			Amount in 7
		FOR THE YEAR	FOR THE YEAR
	PARTICULARS	ENDED	ENDED
		MARCH 31, 2015	MARCH 31, 2014
1	Interest Income*	25,008	2,14,302
2	Miscellaneous Income	-	-
		25,008	2,14,302

* Interest Income includes interest on fixed deposits of earlier year of ₹22,258 (Previous Year ₹Nil)

11. EMPLOYEE BENEFITS EXPENSE

			Amount in ₹
	PARTICULARS	FOR THE YEAR ENDED MARCH 31, 2015	FOR THE YEAR ENDED MARCH 31, 2014
1	Deputation Charges	4,79,265	19,49,803
2	Staff Welfare Expenses	· _	6,862
		4,79,265	19,56,665

12. OTHER EXPENSES

FOR THE YEAR ENDED MARCH 31, 2015	FOR THE YEAR ENDED MARCH 31, 2014
7,355	10,324
5,500	6,179
25,000	25,000
1,200	-
39,055	41,503
	ENDED MARCH 31, 2015 7,355 5,500 25,000 1,200

13. In the opinion of the Board, all the assets have a value on realization in the ordinary course of business at least equal to the amount at which they are stated in the financial statements.

14. RELATED PARTY TRANSACTIONS

Disclosure as required by the Accounting Standard – 18 are given below:

- (a) Particulars of related parties, which control or are under common control with the Company
 - (i) Name of the Company : Neuland Laboratories Limited Nature of Relationship : Holding Company Description of Transactions

Amount in ₹

	Amountin	
Description	For the Year ended March 31, 2015	For the Year ended March 31, 2014
In the Nature of Reimbursement		
- Deputation Charges	4,79,265	19,49,803
- Rates and Taxes	1,320	-
- Professional Charges	4,000	-
- Other Expenses	-	· -
Balance Outstanding Payable	13,85,573	8,44,808

15. EARNINGS PER SHARE (EPS)

Computation of Basic and Diluted Earnings per Share

x		Amount in ?	
Description	For the Year ended March 31, 2015	For the Year ended March 31, 2014	
I. Net Profit / (Loss)	(4,93,312)	(17,83,866)	
II. Weighted average number of equity shares for computation of earnings per share			
- Basic and Diluted	5,11,016	5,11,016	
III. Earnings per Share			
- Basic and Diluted •	(0.97)	(3.49)	

16. Contingent Liabilities & Capital Commitment

- (a) Contingent Liabilities: ₹Nil (Previous year ₹ Nil)
- (b) Estimated amount of contracts remaining to be executed on Capital account and not provided for (net of advances) ₹ Nil (Previous Year ₹Nil)

17. Disclosure required by Micro, Small and Medium Enterprises (Development) Act, 2006.

As per requirement of Section of 22 of Micro, Small & Medium Enterprises Development Act, 2006 following information is disclosed:

10110101			Amount in ₹
SI. No.	Description	For the Year ended. March 31, 2015	For the Year ended March 31, 2014
(i)	Principal amount remaining unpaid to any supplier as at the end of each accounting year.	-	-
(ii)	Interest due on (i) above remaining unpaid.	-	-
(iii)	Amounts paid beyond the appointed day during the accounting year	-	
(iv)	Interest paid on (iii) above	-	-
(v)	Interest due and payable on (iii) above	-	_
(vi)	Interest accrued and remaining unpaid at the end of the accounting year.	-	-
(vii)	Interest remaining unpaid of the previous years for the purpose of disallowance under the Income Tax Act, 1961		-

The above information regarding Micro, Small and Medium Enterprises has been determined to the extent such parties have been identified on the basis of information available with the Company. This has been relied upon by the auditors.

- **18.** Additional Information pursuant to the provisions of Paragraph 5 (viii) of Schedule VI to the Companies Act, 1956 NIL
- 19. Previous year figures have been regrouped / re-classified wherever necessary.

Per our report attached For **B. Srinivasa Rao & Co.** Chartered Accountants ICAI Firm Regn No. 008763S For and on behalf of the Board

D. Sucheth/Rao Director

Henjek Rotmensch

D. Saharsh Rao

Director

CH ANAND Partner Membership No.: 222732

Place: Hyderabad Date: May 7, 2015

Director